Nonalcoholic fatty liver disease: another leap forward.

Nonalcoholic fatty liver disease: another leap forward.
复制标题

DOI:
10.1038/s41575-020-00406-0
复制
发表时间:
2021-03
期刊:
Nature reviews. Gastroenterology & hepatology
影响因子:
--
通讯作者:
Abdelmalek MF
Abdelmalek MF
中科院分区:
其他
文献类型:
--
作者:
Abdelmalek MF

文献摘要

参考文献

被引文献

相似文献

2020年,非酒精性脂肪肝的机制、诊断和治疗方面取得了实质性进展。关键进展包括识别细胞和组织特征以提供对病理生理学的新见解、非侵入性诊断的进步以及公布第一个 III 期试验的中期结果以证明肝纤维化的改善。人体肝脏组织的空间分辨 3D 模型可识别定量多参数细胞和组织特征,以定义疾病进展并为非酒精性脂肪肝疾病病理生理学提供新见解。 FibroScan-AST (FAST) 评分可非侵入性地识别有进展性非酒精性脂肪性肝炎 (NASH) 风险的患者,以进行临床试验和临床实践,从而减少不太可能患有重大疾病的患者进行不必要的肝活检。 III 期 REGENERATE 18 个月中期分析的积极结果表明,NASH 相关肝纤维化出现剂量依赖性改善,这一结果很可能带来临床益处。
In 2020, there have been substantial advances in nonalcoholic fatty liver disease mechanisms, diagnostics and treatment. Key developments include the identification of a cellular and tissue signature to provide new insights into pathophysiology, advancements in non-invasive diagnostics and publication of interim results of the first phase III trial to demonstrate improvement in hepatic fibrosis. Spatially resolved 3D models of human liver tissue identify quantitative multiparametric cellular and tissue signatures to define disease progression and provide new insights into nonalcoholic fatty liver disease pathophysiology. The FibroScan-AST (FAST) score non-invasively identifies patients at risk of progressive nonalcohoholic steatohepatitis (NASH) for clinical trials and potentially in clinical practice, reducing unnecessary liver biopsies in patients unlikely to have significant disease. The positive results of the phase III REGENERATE month-18 interim analysis demonstrated a dose-dependent improvement in NASH-related hepatic fibrosis, an outcome that is reasonably likely to render a clinical benefit.
DOI: 10.1053/j.gastro.2020.08.004
发表时间: 2021-01-01
期刊: GASTROENTEROLOGY
影响因子: 29.4
作者:
Harrison, Stephen A.;Neff, Guy;Lieu, Hsiao D.
通讯作者: Lieu, Hsiao D.
DOI: 10.1053/j.gastro.2015.04.043
发表时间: 2015-08
期刊: Gastroenterology
影响因子: 29.4
作者:
Angulo P;Kleiner DE;Dam-Larsen S;Adams LA;Bjornsson ES;Charatcharoenwitthaya P;Mills PR;Keach JC;Lafferty HD;Stahler A;Haflidadottir S;Bendtsen F
通讯作者: Bendtsen F
DOI: 10.1038/s41591-019-0660-7
发表时间: 2019-12-01
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Segovia-Miranda, Fabian;Morales-Navarrete, Hernan;Zerial, Marino
通讯作者: Zerial, Marino
DOI: 10.1016/s2468-1253(19)30383-8
发表时间: 2020-04-01
影响因子: 35.7
作者:
Newsome, Philip N.;Sasso, Magali;Harrison, Stephen A.
通讯作者: Harrison, Stephen A.
DOI: 10.1002/hep4.1107
发表时间: 2017-11
影响因子: 5.1
作者:
Iruarrizaga-Lejarreta M;Varela-Rey M;Fernández-Ramos D;Martínez-Arranz I;Delgado TC;Simon J;Juan VG;delaCruz-Villar L;Azkargorta M;Lavin JL;Mayo R;Van Liempd SM;Aurrekoetxea I;Buqué X;Cave DD;Peña A;Rodríguez-Cuesta J;Aransay AM;Elortza F;Falcón-Pérez JM;Aspichueta P;Hayardeny L;Noureddin M;Sanyal AJ;Alonso C;Anguita J;Martínez-Chantar ML;Lu SC;Mato JM
通讯作者: Mato JM